Acadia Pharmaceuticals (ACAD) said late Monday the US Patent and Trademark Office issued a notice of allowance for a patent application covering weight-banded dosing of trofinetide for the treatment of Rett syndrome.

The company said the patent, if issued, is expected to provide US protection for trofinetide through March 28, 2041, including six months of pediatric exclusivity, extending protection by nearly five years.

Trofinetide is marketed in the US as "Daybue" and "Daybue Stix" for the treatment of Rett syndrome in adults and children age 2 and older. The drug is also covered by a method-of-use patent that expires in July 2036, the company said.